Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 9:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 140 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Metastatic Ewing Sarcoma
Interventions
Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Actinomycin, Irinotecan, Cabozantinib, Topotecan, Temozolomide, Etoposide, Liposomal doxorubicin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 16 more
Conditions
Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Interventions
tolododekin alfa, Cemiplimab
Drug
Lead sponsor
Ankyra Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
Conditions
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
NN3201
Drug
Lead sponsor
Novelty Nobility, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
Conditions
Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Radiation Therapy, TLR4 Agonist GLA-SE
Other · Radiation · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions
LV305, G305, LV305-matching placebo, G305-matching placebo
Biological · Other
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
12 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Conditions
Sarcoma
Interventions
CBT-1®
Drug
Lead sponsor
CBA Research
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Santa Monica, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
Conditions
Solid Organ Cancers
Interventions
GL-ONC1
Biological
Lead sponsor
Andrew Lowy
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Conditions
Leiomyosarcoma
Interventions
Unesbulin, Dacarbazine, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 18 more
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma, Osteoblastic Osteosarcoma, Recurrent Osteosarcoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
10 Years to 20 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Monrovia, California
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Interventions
INNO-206, Doxorubicin
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
15 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 2 more
Conditions
Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more
Conditions
Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions
Abemaciclib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Gemcitabine
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
Interventions
Avapritinib, midazolam
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Conditions
Locally Advanced or Metastatic Solid Tumor
Interventions
Rebastinib, Paclitaxel
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 10 more
Completed Phase 3 Interventional Results available

A Study of Nilotinib Versus Imatinib in GIST Patients

NCT00785785
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
Nilotinib (AMN107), imatinib (STI571)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
28
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Duarte, California + 22 more
Conditions
Sarcoma
Interventions
Trabectedin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Conditions
Neoplasms
Interventions
Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
11
States / cities
Des Moines, Iowa • Kalamazoo, Michigan • Papillion, Nebraska + 5 more
Conditions
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Interventions
170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
15 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Santa Monica, California
Conditions
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions
Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
1,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
181
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma, Progressive Disease, Prostate Carcinoma Metastatic in the Bone, Prostate Carcinoma Metastatic in the Soft Tissue, PSA Progression, Stage IVB Prostate Cancer AJCC v8, Testosterone Less Than 50 ng/dL
Interventions
Recombinant EphB4-HSA Fusion Protein
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois